Kymera Therapeutics Inc [KYMR] stock is trading at $47.62, down -0.08%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KYMR shares have gain 60.66% over the last week, with a monthly amount glided 63.59%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kymera Therapeutics Inc [NASDAQ: KYMR] stock has seen the most recent analyst activity on June 03, 2025, when Morgan Stanley upgraded its rating to a Overweight but kept the price target unchanged to $79 for it. Previously, B. Riley Securities upgraded its rating to Buy on June 03, 2025, and kept the price target unchanged to $60. On June 02, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $51 on the stock. Citigroup initiated its recommendation with a Buy and recommended $52 as its price target on March 13, 2025. BTIG Research started tracking with a Buy rating for this stock on December 10, 2024, and assigned it a price target of $60. In a note dated December 06, 2024, BMO Capital Markets initiated an Market Perform rating and provided a target price of $55 on this stock.
Kymera Therapeutics Inc [KYMR] stock has fluctuated between $19.44 and $53.27 over the past year. Currently, Wall Street analysts expect the stock to reach $57 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $47.62 at the most recent close of the market. An investor can expect a potential return of 19.7% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
Kymera Therapeutics Inc [NASDAQ:KYMR] reported sales of 58.88M for the trailing twelve months, which represents a growth of 114.83%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -4.72%, Pretax Profit Margin comes in at -4.09%, and Net Profit Margin reading is -4.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.3 and Total Capital is -0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 46.44 points at the first support level, and at 45.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 49.39, and for the 2nd resistance point, it is at 51.16.
Ratios To Look Out For
For context, Kymera Therapeutics Inc’s Current Ratio is 8.49. Also, the Quick Ratio is 8.49, while the Cash Ratio stands at 1.53. Considering the valuation of this stock, the price to sales ratio is 52.67, the price to book ratio is 3.94.
Transactions by insiders
Recent insider trading involved Esposito Pamela, Director, that happened on Jun 03 ’25 when 5000.0 shares were sold. Director, Ridloff Elena completed a deal on Jun 03 ’25 to sell 12000.0 shares. Meanwhile, Chief Executive Officer Mainolfi Nello sold 30000.0 shares on Jun 03 ’25.
